1. I helped Mr. V, checked up on his many picks & even told him to concentrate on $ITMN when it was roughly $25, which it later sold for $75.

  2. It s easy to think Roche got a bad deal from $ITMN M&A, but pirfenidone price tag and IPF mkt deliver sig. earnings https://www.retailinvestor360.com/biotech/80-intermune-inc-complete-dominancy-in-fibrotic-lung-disease-market.html

  3. $SLTD this is my 2nd best stock pick other than $ITMN

  4. $AAVL could fetch up to 5-8B+ in a buyout if it s huge advance over Eylea. $ITMN was acquired for 8B after approval as comparison.

  5. If $ITMN was worth $74 & WS valued it at $10: I don t see how $MNKD cannot worth at least $30 when the market is valuing it at $5.45.

  6. When I recommended $ITMN for $64, it was only on sales for $10, naysayers thought I was nut: The firm later sold for $74 to $ROG

  7. Biopharmas Leading the Pack: Intercept, Regeneron, MannKind, InterMune and Sanofi. $REGN $ITMN $MNKD $SNY

  8. When I picked up $ITMN, it was $10 and it took off until it was sold to $ROG for $74: That should have been $MNKD! https://www.retailinvestor360.com/biotech/80-intermune-inc-complete-dominancy-in-fibrotic-lung-disease-market.html

  9. I am very happy for $ITMN and $ROG and more so for patients as there are hopes for IPD, where there was none https://www.retailinvestor360.com/biotech/80-intermune-inc-complete-dominancy-in-fibrotic-lung-disease-market.html

  10. $ACAD be easy now.. be easy.. I have not been this excited since $ITMN buyout

  11. In biopharma, M&A can be as larger as $8b like $ROG buyout of $ITMN. $PFE is willing to pay $17b for $HSP https://www.retailinvestor360.com/biotech/805-the-md-360-reports-on-corporate-strategy-of-pfizer-and-hospira-acquisition-deal.html

  12. Familiar ETF Friend Will Enjoy a Pharmacyclics Sale http://www.etftrends.com/2015/02/familiar-etf-friend-will-enjoy-a-pharmacyclics-sale/ $JNJ $NVWS $FBT $PCYC $ITMN

  13. $ITMN misses the Estimize EPS Consensus by 1c and the Estimize Revenue Consensus by $5.65M - http://www.estimize.com/itmn/fq4-2014?utm_content=beat_or_miss&utm_medium=tweet&utm_source=stocktwits

  14. $ITMN reports FQ4 earnings of -72c EPS and $35.70M Revs - http://www.estimize.com/itmn/fq4-2014?utm_content=release_actuals&utm_medium=tweet&utm_source=stocktwits

  15. $ITMN reports before the open tomorrow, Estimize Consensus +0.05 EPS and -1.51M Revs compared to WS http://www.estimize.com/itmn/fq4-2014?utm_content=prerelease&utm_medium=tweet&utm_source=stocktwits

  16. This firm right here was a match made in heaven with Roche, the M&A that was imminent https://www.retailinvestor360.com/biotech/80-intermune-inc-complete-dominancy-in-fibrotic-lung-disease-market.html $ITMN $ROG

  17. $MRTX It could be next $PBYI $ITMN http://www.mirati.com/programs/ Loved by Bakers they hold more than 19%

  18. Complete Dominancy In Fibrotic Lung Disease Market https://www.retailinvestor360.com/biotech/80-intermune-inc-complete-dominancy-in-fibrotic-lung-disease-market.html $ITMN $ROG

  19. @MakeMyLuck I bought $ITMN at 10 before anyone knew what it was . Locked profit 14. It went to 75...small profit won t make you rich

  20. Bio Leading the Pack: Intercept, Regeneron, MannKind, InterMune & Sanofi. https://www.retailinvestor360.com/biotech/749-360-md-reports-on-biopharmas-leading-the-pack-intercept-regeneron-mannkind-intermune-and-sanofi.html $SNY $MNKD $REGN $ITMN $ICPT

  21. New bullish conversation activity in $ITMN. Had been quiet for past 48 hours.

  22. If anyone every say InterMune Inc, you say, Complete Dominance in Fibrotic Lungs Disease Market! $ITMN $ROG https://www.retailinvestor360.com/biotech/80-intermune-inc-complete-dominancy-in-fibrotic-lung-disease-market.html

  23. The 360-MD Report has not failed to deliver for our 360-family of expert readers, that is! https://www.retailinvestor360.com/biotech/749-360-md-reports-on-biopharmas-leading-the-pack-intercept-regeneron-mannkind-intermune-and-sanofi.html $ICPT, $MNKD, $SNY, $ITMN

  24. $MNKD $ICPT $OME $ITMN $BRLI How to Be Opportune as Intelligent Investors in Chaotic Markets https://www.retailinvestor360.com/biotech/768-how-to-be-opportune-as-intelligent-investors-in-chaotic-markets.html

  25. $ITMN $ROG Forever treasures the sweet memories seeing how the thesis of InterMune unfolded, after years of waiting https://www.retailinvestor360.com/biotech/80-intermune-inc-complete-dominancy-in-fibrotic-lung-disease-market.html